NO-Donor Dihydroartemisinin Derivatives as Multitarget Agents for the Treatment of Cerebral Malaria.

Hybrid products in which the dihydroartemisinin scaffold is combined with NO-donor furoxan and NONOate moieties have been synthesized and studied as potential tools for the treatment of cerebral malaria (CM). The designed products were able to dilate rat aorta strips precontracted with phenylephrine with a NO-dependent mechanism. All hybrid compounds showed preserved antiplasmodial activity in vitro and in vivo against Plasmodium berghei ANKA, comparable to artesunate and artemether. Hybrid 10, selected for additional studies, was capable of increasing survival of mice with late-stage CM from 27.5% to 51.6% compared with artemether. Artemisinin-NO-donor hybrid compounds show promise as potential new drugs for treating cerebral malaria.

[1]  J. Frangos,et al.  Cerebral tissue oxygenation impairment during experimental cerebral malaria , 2013, Virulence.

[2]  J. Frangos,et al.  Transdermal Glyceryl Trinitrate as an Effective Adjunctive Treatment with Artemether for Late-Stage Experimental Cerebral Malaria , 2013, Antimicrobial Agents and Chemotherapy.

[3]  J. Frangos,et al.  Nitric Oxide Synthase Dysfunction Contributes to Impaired Cerebroarteriolar Reactivity in Experimental Cerebral Malaria , 2013, PLoS pathogens.

[4]  X. Su,et al.  Malaria biology and disease pathogenesis: insights for new treatments , 2013, Nature Medicine.

[5]  J. Frangos,et al.  A lactate dehydrogenase ELISA-based assay for the in vitro determination of Plasmodium berghei sensitivity to anti-malarial drugs , 2012, Malaria Journal.

[6]  J. Frangos,et al.  S-nitrosoglutathione Prevents Experimental Cerebral Malaria , 2012, Journal of Neuroimmune Pharmacology.

[7]  J. Frangos,et al.  Exogenous nitric oxide decreases brain vascular inflammation, leakage and venular resistance during Plasmodium berghei ANKA infection in mice , 2011, Journal of Neuroinflammation.

[8]  John A. Frangos,et al.  Nitric oxide protection against murine cerebral malaria is associated with improved cerebral microcirculatory physiology. , 2011, The Journal of infectious diseases.

[9]  S. Parapini,et al.  Amodiaquine analogues containing NO-donor substructures: synthesis and their preliminary evaluation as potential tools in the treatment of cerebral malaria. , 2011, European journal of medicinal chemistry.

[10]  J. Frangos,et al.  Artemether and Artesunate Show the Highest Efficacies in Rescuing Mice with Late-Stage Cerebral Malaria and Rapidly Decrease Leukocyte Accumulation in the Brain , 2011, Antimicrobial Agents and Chemotherapy.

[11]  Kamolrat Silamut,et al.  Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial , 2010, The Lancet.

[12]  R. Price,et al.  Increased Asymmetric Dimethylarginine in Severe Falciparum Malaria: Association with Impaired Nitric Oxide Bioavailability and Fatal Outcome , 2010, PLoS pathogens.

[13]  J. Frangos,et al.  Immunopathology and Infectious Diseases Murine Cerebral Malaria Is Associated with a Vasospasm-Like Microcirculatory Dysfunction , and Survival upon Rescue Treatment Is Markedly Increased by Nimodipine , 2010 .

[14]  C. Newton,et al.  Diagnosis and management of the neurological complications of falciparum malaria , 2009, Nature Reviews Neurology.

[15]  Y. Swica,et al.  Proposal for the inclusion of misoprostol in the WHO model list of essential medicines , 2009 .

[16]  R. Price,et al.  Impaired nitric oxide bioavailability and l-arginine–reversible endothelial dysfunction in adults with falciparum malaria , 2007, The Journal of experimental medicine.

[17]  J. Frangos,et al.  Low nitric oxide bioavailability contributes to the genesis of experimental cerebral malaria , 2006, Nature Medicine.

[18]  B. Neville,et al.  Persistent neurocognitive impairments associated with severe falciparum malaria in Kenyan children , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[19]  N. Anstey,et al.  Low plasma arginine concentrations in children with cerebral malaria and decreased nitric oxide production , 2003, The Lancet.

[20]  N. Anstey,et al.  Nitric oxide in Tanzanian children with malaria: inverse relationship between malaria severity and nitric oxide production/nitric oxide synthase type 2 expression , 1996, The Journal of experimental medicine.

[21]  P. Martorana,et al.  Cardiovascular actions of the furoxan CAS 1609, a novel nitric oxide donor , 1995, British journal of pharmacology.